GRF · Grifols, S.A. Class A

9.68

EUR

-0.264 (-2.654%)

08/10/2026 12:00:00 AM

Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

Euro6.01B

18.10

EV/EBITDA

10.4

DIV Yield

1.8%

Payout Ratio

32%

MQV Rating

5Very Weak

As at 08/10/2026 12:00:00 AM

Price Chart

Description

Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. It operates through the following segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma Segment includes all activities related with products deriving from human plasma for therapeutic use. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols i Roig in 1909 and is headquartered in Barcelona, Spain.

All-Companies
All-Consensus
Consensus Cheap
EMA 125 Breakup
HALO 100
HALO 200
HALO 50
HALO All
HALO Consensus Value
HALO Dividend Growth
HALO Price Momentum
HALO Value
Short Term Trend - Long

Key Fundamentals

EPS 3 yr Growth

92.40%

EBITDA Margin

22.40%

Operating Cashflow

€1,047m

Free Cash Flow Return

7.40%

ROIC

2.90%

Interest Coverage

2.70

Quick Ratio

0.90

Performance

52 weeks range

Low 8.43 - 12.36

Trade Value (12mth)

US$5,166,465.00

1 week

4.17%

1 month

-0.08%

YTD

-11.14%

1 year

-17.48%

All time high

34.31

Additional Data

Shares Outstanding (Fully Diluted)

681m

HALO Sector

Healthcare

Next Company Report Date

04-Mar-27

Next Ex Dividend Date

30-Jun-26

Next Dividend Pay Date

02-Jul-26

Reporting Currency

EUR

Short Sell (% of issue)

0.00

Consensus

Unlock full consensus

Consensus score

/10

Recommendation

Buy

Target price

Deviation

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Very Strong

Event

Very Strong

Halo Model

Mqv

Very Weak

Garp

Strong

Mqv Small

Neutral

Momentum

Price

Very Strong

Earnings

Very Weak

Growth

Earnings

Strong

Dividends

Very Strong

Quality

Capital Efficiency

Weak

Balance Sheet

Very Weak

Valuation

Unlock full dataset

Value

Consensus

Yield

News & Announcements

No announcements available.

Key Stakeholders

Name	Title
Grifols Roura Family	Individual
Scranton Enterprises BV	Private Company
Grifols Gras Family	Individual
Employees Provident Fund Board	Pension Fund
Tomás Dagá Gelabert	Individual